期刊文献+

我院2011-2014年结直肠癌患者化疗用药分析 被引量:1

Analysis of the Application of Antineoplastic Drugs in Patients with Colorectal Cancer in Our Hospital during 2011-2014
原文传递
导出
摘要 目的:为结直肠癌患者化疗提供方案以及用药参考。方法:查阅我院2011-2014年化疗的结直肠癌住院患者的病历及医嘱,对化疗方案和药物的使用及用药不合理现象进行回顾性统计、分析。结果:共纳入结直肠癌患者593例,化疗频次1 940次,主要从化疗的适应证、方案的选择、化疗过程、化疗的时间及周期等方面对化疗方案选择进行分析;用药不合理409例,主要从药物剂量、溶剂选择、药物浓度等方面进行统计分析,不合格率为21.08%。结论:我院结直肠癌患者抗肿瘤药的使用以及化疗方案的选择基本合理,但仍存在一定的不足,在今后的临床应用中,有待进一步改进。 OBJECTIVE: To provide reference for medication and chemotherapy in patients with colorectal cancer. METH- ODS : Through retrospective study, case histories and doctor' s advice of the colorectal cancer patients receiving chemotherapy in our hospital during 2011-2014 were consulted to analyze the chemotherapy, medication and irrational drug use. RESULTS: A total of 593 cases of colorectal cancer patients with chemotherapy frequency of 1 940 times were collected to analyze the choice of che- motherapy regimen mainly from the following aspects: indications of chemotherapy, choice of chemotherapy regimen, chemothera- py process and chemotherapy period. There was 409 cases of irrational drug use according to the analysis of drug dosage, selection of solvents and drug concentration, the unqualified rate was 21.08% . CONCLUSIONS: The medication and chemotherapy in pa- tients with colorectal cancer in our hospital are basically rational, but there are still certain problems and shortcomings. In future clinical applications, the medication and chemotherapy need to be improved.
出处 《中国药房》 CAS 北大核心 2015年第32期4485-4487,共3页 China Pharmacy
关键词 结直肠癌 化疗 抗肿瘤药 合理用药 Colorectal cancer Chemotherapy Antineoplastic drug Rational drug use
  • 相关文献

参考文献13

  • 1Jemal A, Siegel R, Xu j, et al. Cancer statistics, 2010[J].Cancer J Clin y2010 y60(5)211.
  • 2Gravalos C,Garcia-Escobar I, Garcia-Alfonso P, et al.Ad-juvant chemotherapy for stages II,HI and IV of coloncancer[J]. Clin Transl 0.co/,2009,11(8) :526.
  • 3Franko J,Shi Q,Goldman CD,et “/.Treatment of colorec-tal peritoneal carcinomatosis with systemic chemothera-py: a pooled analysis of north central cancer treatmentgroup phase HI trials N9741 and N9841[J]. J Clin Oncol,2012,30(3):263.
  • 4Coleman MP,Quaresma M,Berrino F,et al.Cancer surviv-al in five continents : a worldwide population-based study(CONCORD)[J]. Lancet Onco/,2008,9(8) :730.
  • 5Andre T,Boni C,Navarro M,et al.Improved overall sur-vival with oxaliplatin,fluorouracil,and leucovorin as ad-juvant treatment in stage II or DI colon cancer in the MO-SAIC trial[J]. JC/m Owco/,2009,27(19) :3 109.
  • 6Ribic CM,Sargent DJ,Moore MJ.Tumor microsatellite-in-stability status as a predictor of benefit from fluoroura-cil-based adjuvant chemotherapy for colon cancer[J]. NEngl J Med, 2003,349(3): 247.
  • 7Bosman FT,Yan P, Tejpar S,et al,Tissue biomarker de-velopment in a multicentre trial context : a feasibility studyon the PETACC3 stage II and HI colon cancer adjuvanttreatment trial[J]. Clin Cancer Res,2009,15(17):5 528.
  • 8Twelves C,Wong A,Nowacki MP,et al.Capecitabine asAdjuvant Treatment for Stage III Colon Cancer [J]. N&g/JAfec/,2005,352(26):2 696.
  • 9Hsiao SC,Lin JF,Chuang MT.Retrospectively compara-tive evaluation of the first- and second-line chemotherapywith campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastaticcolorectal cancer[J]. Int Surg, 2009,94(4) :298.
  • 10Shirao K, Ohtsu A, Takada H^et al.Phase II study of oralS-l for treatment of metastatic colorectal carcinoma [J].Ca.cer,2004,100(ll):2 355.

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部